Loading institutional data...
Loading institutional data...
Held by 316 of 5,944 reporting institutions (95th percentile) — extremely crowded.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Solve the discounted cash flow backwards, then stress-test the assumptions.
To be worth $79.47 today, the market must believe free cash flow compounds 16.4%/yr for a decade (off $47M normalized FCF).
The market's 16.4% is more conservative than its 9-yr track record.
2-stage DCF · 0.02B shares · net debt -$28M
mean 34.8% · volatility σ 75% · implied rate exceeded in 5/9 yrs
Central path = implied 16.4%/yr growth; shaded band = ±1σ (75%) of this company's historical FCF volatility, widening with time. The wider the band, the less certain the growth.
Reverse DCF: rather than guessing a fair value, we solve for the growth the current price implies, then you stress-test the assumptions. Enterprise value of the FCF stream, less net debt, ÷ shares. Educational — not a recommendation.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
6/8 of the 9 checks — 1 couldn't be scored (see above), so the score is out of the 8 with data.
Safe > 2.99 · grey 1.81–2.99 · distress < 1.81
Eight indices comparing this year to last (receivables, margins, asset quality, growth, accruals, leverage). Above −1.78 suggests possible manipulation; below −2.22 is clean.
A screen, not proof — high growth alone can raise it.
Earnings are backed by cash (FCF ≥ net income) — high quality. Lower/negative accruals = higher quality (Sloan).
Comfortably covers interest.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
The dividend is comfortably covered — only 24% of free cash flow, leaving room to grow it and fund buybacks. Last year: $18M dividends + $2M buybacks = $20M returned on $74M FCF.
9 consecutive years of dividend increases · 18%/yr.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A balanced mix of reinvestment and shareholder returns.
Reinvestment has been productive — operating income grew well per dollar put in. Current ROIC on all capital: 15%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Insufficient EBITDA/debt history.
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Interest is easily covered by operating profit.
Cash vs short-term debt unavailable.
Short-term / long-term split not separately reported.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Educational — not a recommendation.
EOD close · as of 2026-09-17
No material risks flagged.
Where each multiple sits in its own 14-yr range · 60th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 14-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
Returns are margin-driven, not leverage-driven — higher quality.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
High operating leverage: profit moved 2.2× as fast as sales — great in an upturn, painful in a downturn.
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 30.0 | 31.9 | 34.6 | 34.3 | 35.1 | 34.3 | 31.4 | 28.5 |
| Gross Profit | 70.0 | 68.1 | 65.4 | 65.7 | 64.9 | 65.7 | 68.6 | 71.5 |
| R&D | 7.8 | 7.9 | 7.8 | 7.6 | 8.2 | 8.8 | 7.1 | 5.7 |
| SG&A | 16.8 | 16.3 | 17.4 | 16.5 | 17.8 | 16.5 | 16.5 | 16.8 |
| Operating Income | 26.7 | 18.1 | 22.3 | 23.6 | 16.6 | 19.0 | 23.8 | 27.2 |
| Income Tax | 5.2 | 3.2 | 4.7 | 4.8 | 4.2 | 4.8 | 5.8 | 7.0 |
| Net Income | 21.7 | 15.3 | 16.4 | 17.4 | 12.7 | 15.6 | 20.0 | 23.1 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on LMAT: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.
EOD close · as of 2026-09-17
How a revenue dollar becomes profit — FY2025
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $249.6M 100.0% | $219.9M 100.0% | $193.5M 100.0% | $161.7M 100.0% | $154.4M 100.0% | $129.4M 100.0% | $117.2M 100.0% | $105.6M 100.0% | $100.9M 100.0% | $89.2M 100.0% |
| Cost of Revenue | $71.1M 28.5% | $69.0M 31.4% | $66.4M 34.3% | $56.8M 35.1% | $53.0M 34.3% | $44.7M 34.6% | $37.4M 31.9% | $31.6M 30.0% | $30.2M 29.9% | $26.2M 29.4% |
| Cost of Products | — | — | — | — | — | — | — | — | $30.2M 29.9% | $26.2M 29.4% |
| Gross Profit | $178.5M 71.5% | $150.9M 68.6% | $127.0M 65.7% | $104.9M 64.9% | $101.4M 65.7% | $84.6M 65.4% | $79.9M 68.1% | $73.9M 70.0% | $70.7M 70.1% | $62.9M 70.6% |
| Research & Development | $14.1M 5.7% | $15.7M 7.1% | $17.0M 8.8% | $13.3M 8.2% | $11.8M 7.6% | $10.1M 7.8% | $9.3M 7.9% | $8.2M 7.8% | $6.6M 6.6% | $6.1M 6.9% |
| Selling, General & Admin | $42.0M 16.8% | $36.3M 16.5% | $31.8M 16.5% | $28.7M 17.8% | $25.5M 16.5% | $22.5M 17.4% | $19.1M 16.3% | $17.7M 16.8% | $17.0M 16.9% | $14.4M 16.1% |
| Total Operating Expenses | $110.6M 44.3% | $98.6M 44.9% | $90.3M 46.7% | $78.1M 48.3% | $65.0M 42.1% | $55.8M 43.2% | $58.7M 50.0% | $45.7M 43.3% | $49.6M 49.2% | $46.6M 52.3% |
| Operating Income | $67.9M 27.2% | $52.3M 23.8% | $36.7M 19.0% | $26.8M 16.6% | $36.4M 23.6% | $28.8M 22.3% | $21.2M 18.1% | $28.2M 26.7% | $21.1M 20.9% | $16.3M 18.3% |
| Interest Expense | $5.2M 2.1% | $205K 0.1% | $0 0.0% | $0 0.0% | $2.2M 1.4% | $1.3M 1.0% | $0 0.0% | $2K 0.0% | $21K 0.0% | $14K 0.0% |
| Interest & Investment Income | $13.1M 5.2% | $4.9M 2.3% | $3.1M 1.6% | $986K 0.6% | $197K 0.1% | $207K 0.2% | $698K 0.6% | $631K 0.6% | $179K 0.2% | $81K 0.1% |
| Other Income (Expense), net | -$638K -0.3% | -$125K -0.1% | -$314K -0.2% | -$325K -0.2% | -$116K -0.1% | -$329K -0.3% | — | — | — | — |
| Pretax Income | $75.2M 30.1% | $56.9M 25.9% | $39.5M 20.4% | $27.5M 17.0% | $34.3M 22.2% | $27.4M 21.1% | $21.7M 18.5% | $28.4M 26.9% | $21.1M 20.9% | $16.2M 18.2% |
| Income Tax Expense | $17.4M 7.0% | $12.8M 5.8% | $9.4M 4.8% | $6.9M 4.2% | $7.4M 4.8% | $6.1M 4.7% | $3.7M 3.2% | $5.5M 5.2% | $3.9M 3.9% | $5.7M 6.3% |
| Net Income | $57.7M 23.1% | $44.0M 20.0% | $30.1M 15.6% | $20.6M 12.7% | $26.9M 17.4% | $21.2M 16.4% | $17.9M 15.3% | $22.9M 21.7% | $17.2M 17.0% | $10.6M 11.9% |
| Per Share | ||||||||||
| EPS (Basic) | $2.55 | $1.96 | $1.36 | $0.94 | $1.27 | $1.05 | $0.91 | $1.18 | $0.91 | $0.57 |
| EPS (Diluted) | $2.52 | $1.93 | $1.34 | $0.93 | $1.25 | $1.04 | $0.88 | $1.13 | $0.86 | $0.55 |
| Weighted Avg Shares (Basic) | 22.6M | 22.5M | 22.2M | 22.0M | 21.2M | 20.2M | 19.8M | 19.4M | 19.0M | 18.5M |
| Weighted Avg Shares (Diluted) | 22.9M | 22.8M | 22.4M | 22.2M | 21.5M | 20.5M | 20.3M | 20.2M | 20.0M | 19.2M |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Top 40 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
Ranked against 1085 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAX | $1.24T | — | — | — | — | — | — | -34.4% | -34.4% | — | 143 |
| LLY | $1.03T | 50.2× | — | 15.9× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $894.1B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $650.5B | 24.5× | — | 6.9× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $467.1B | 111.9× | 33.4× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| MRK | $368.2B | 20.2× | — | 5.7× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| UNH | $339.9B | 28.4× | 19.7× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| AZN | $257.7B | — | — | — | — | — | — | — | — | — | 1,248 |
| TMO | $248.2B | 37.1× | 31.9× | 5.6× | 3.9% | — | 15.0% | 12.6% | 7.0% | 4.9× | 2,481 |
| AMGN | $204.6B | 26.7× | 17.6× | 5.6× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.8× | 3,014 |
| GILD | $187.3B | 22.3× | 20.4× | 6.4× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| ABT | $178.0B | 27.5× | 19.2× | 4.0× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 1.4× | 2,964 |
| PFE | $157.1B | 20.3× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $150.2B | 42.1× | 31.0× | 6.1× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $136.2B | 48.7× | 37.5× | 13.5× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| VRTX | $131.1B | 33.7× | 28.8× | 10.9× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| BMY | $127.8B | 18.2× | — | 2.6× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,431 |
| MDT | $118.8B | 24.9× | 12.6× | 3.3× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| CVS | $114.7B | 64.9× | 11.5× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| SYK | $107.1B | 33.4× | 18.4× | 4.3× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| MCK | $102.5B | 22.9× | 16.2× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| HCA | $96.4B | 15.1× | — | 1.3× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $91.4B | 16.4× | 15.5× | 0.5× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| REGN | $82.6B | 19.0× | 19.8× | 5.8× | 1.0% | — | 31.4% | 14.4% | 13.6% | 0.5× | 1,336 |
| CI | $72.7B | 12.4× | 5.5× | 0.3× | 11.2% | 21.8% | 2.2% | 14.3% | 14.1% | 0.0× | 1,583 |
| LMAT | $1.8B | 31.5× | 22.7× | 7.3× | 13.5% | 71.5% | 23.1% | 14.7% | 14.7% | — | 316 |
Peers = companies sharing LMAT's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.